Louisiana 2010 Regular Session

Louisiana House Bill HB1095

Introduced
3/29/10  
Refer
3/29/10  
Report Pass
3/31/10  
Engrossed
4/8/10  
Report Pass
5/19/10  
Enrolled
6/16/10  
Chaptered
6/22/10  

Caption

Provides relative to the reporting and accessing of prescription monitoring information (EN NO IMPACT See Note)

Impact

The modifications introduced by HB 1095 are expected to improve the efficiency of prescription monitoring by ensuring timely reporting of controlled substances. This legislative measure not only reinforces the state's ongoing battle against prescription drug misuse but also facilitates law enforcement agencies' ability to investigate potential violations. The changes to report submission frequency aim to provide a more accurate and recent snapshot of prescribing behaviors, which is critical for responding to prescription drug misuse issues effectively.

Summary

House Bill 1095 is designed to enhance Louisiana's Prescription Monitoring Program (PMP) by amending regulations surrounding the reporting and access of prescription data. This bill aims to improve the control of prescription drug abuse by mandating that dispensers report prescription transactions more frequently, specifically within seven days of dispensing. Additionally, the bill outlines who may access this sensitive information, thus intending to balance the needs of law enforcement against patient privacy concerns.

Sentiment

Overall, the sentiment towards HB 1095 appears to be favorable, as it is primarily framed as a necessary step in protecting public health and combating drug abuse. Supporters, including healthcare professionals and law enforcement, view the bill as a proactive measure aimed at encouraging responsible prescribing and dispensing practices. However, there are underlying concerns regarding patient privacy and the potential for misuse of the data collected, suggesting that the bill has elicited some caution among advocacy groups and privacy advocates.

Contention

One notable debate surrounding HB 1095 pertains to the accessibility of the prescription monitoring data. While the intention is to deter drug abuse and support law enforcement efforts, critics are wary about how this information might be utilized, fearing it may infringe on patient privacy rights. Ensuring that access to prescription data is appropriately regulated and protected is a significant point of contention that reflects broader societal concerns about healthcare data management and privacy.

Companion Bills

No companion bills found.

Previously Filed As

LA SB96

Provides relative to the prescription monitoring program. (gov sig) (EN SEE FISC NOTE SG RV)

LA SB53

Provides relative to prescription monitoring information. (8/1/19) (EN NO IMPACT See Note)

LA HB288

Provides for access to information under the Prescription Monitoring Program Act

LA HB355

Provides relative to access to state prescription monitoring program information

LA HB197

Provides relative to the Prescription Monitoring Program (EN +$21,250 SG RV See Note)

LA HB275

Provides with respect to the subpoenaing of prescription monitoring information

LA SB556

Amends frequency of reporting prescription dispensing of certain substances to the state prescription monitoring board. (8/1/14)

LA HB304

Provides relative to sharing of prescription monitoring program information with equivalent programs of other states

LA HB436

Requires drug manufacturers to provide information regarding prescription drug prices (EN NO IMPACT See Note)

LA SB112

Authorizes sharing of prescription monitoring program information with prescription monitoring programs located in other states. (8/1/12)

Similar Bills

No similar bills found.